

Stephen Holt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2182/publications.pdf>

Version: 2024-02-01

139
papers

4,873
citations

81900

39
h-index

102487

66
g-index

143
all docs

143
docs citations

143
times ranked

5803
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3â€“4 CKDâ€” results from a placebo-controlled randomized trial. Nephrology Dialysis Transplantation, 2023, 38, 344-351.	0.7	2
2	An analysis of antibody responses and clinical sequelae of the Sinopharm <scp>HB02 COVID19</scp> vaccine in dialysis patients in the <scp>United Arab Emirates</scp>. Nephrology, 2022, 27, 260-268.	1.6	11
3	The Omicron <scp>COVID</scp>â€“19 threat to dialysis patients is dramatically lower than previous variants. Nephrology, 2022, 27, 725-726.	1.6	2
4	Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nature Communications, 2022, 13, .	12.8	19
5	Hepatitis B related dilemmas in the renal unit. Nephrology, 2021, 26, 287-293.	1.6	4
6	Inferiority of arteriovenous grafts, in comparison to autogenous fistulas, is underestimated by standard survival measures alone. ANZ Journal of Surgery, 2021, 91, 162-167.	0.7	6
7	The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: <i>post hoc</i> analysis from a randomized controlled clinical trial. Nephrology Dialysis Transplantation, 2021, 36, 713-721.	0.7	30
8	Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease. JBMR Plus, 2021, 5, e10497.	2.7	5
9	Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody. BMC Nephrology, 2021, 22, 198.	1.8	11
10	The Introduction of cPRA and Its Impact on Access to Deceased Donor Kidney Transplantation for Highly Sensitized Patients in Australia. Transplantation, 2021, 105, 1317-1325.	1.0	5
11	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
12	Aortic stiffness and central systolic pressure are associated with ambulatory orthostatic BP fall in chronic kidney disease. Journal of Nephrology, 2020, 33, 317-324.	2.0	10
13	Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease. BMC Nephrology, 2020, 21, 279.	1.8	6
14	Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association?. BMC Nephrology, 2020, 21, 293.	1.8	2
15	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	6.1	52
16	Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized ControlledÂ Trial. Kidney International Reports, 2020, 5, 1432-1447.	0.8	15
17	The potential role of antibodies against minor blood group antigens in renal transplantation. Transplant International, 2020, 33, 841-848.	1.6	4
18	Monitoring skin temperature at the wrist in hospitalised patients may assist in the detection of infection. Internal Medicine Journal, 2020, 50, 685-690.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Outcomes of cinacalcet withdrawal in Australian dialysis patients. <i>Internal Medicine Journal</i> , 2019, 49, 48-54.	0.8	9
20	Klotho-FGF23 interactions and their role in kidney disease: a molecular insight. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4705-4724.	5.4	21
21	Profiling histone modifications in the normal mouse kidney and after unilateral ureteric obstruction. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F606-F615.	2.7	2
22	Diagnostic Tests for Vascular Calcification. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 445-463.	1.4	23
23	TGF- β 1 modifies histone acetylation and acetyl-coenzyme A metabolism in renal myofibroblasts. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F517-F529.	2.7	27
24	Green dialysis survey: Establishing a baseline for environmental sustainability across dialysis facilities in Victoria, Australia. <i>Nephrology</i> , 2019, 24, 88-93.	1.6	22
25	Biochemical transformation of calciprotein particles in uraemia. <i>Bone</i> , 2018, 110, 355-367.	2.9	49
26	Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation. <i>American Journal of Nephrology</i> , 2018, 47, 376-384.	3.1	39
27	Calciprotein Particle Formation in Peritoneal Dialysis Effluent is Dependent on Dialysate Calcium Concentration. <i>Peritoneal Dialysis International</i> , 2018, 38, 286-292.	2.3	11
28	Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. <i>Bone</i> , 2018, 114, 14-21.	2.9	26
29	Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. <i>BMC Nephrology</i> , 2018, 19, 113.	1.8	16
30	Changes in bone microarchitecture following kidney transplantation—Beyond bone mineral density. <i>Clinical Transplantation</i> , 2018, 32, e13347.	1.6	9
31	Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. <i>Seminars in Dialysis</i> , 2018, 31, 487-499.	1.3	40
32	High-intensity physical exercise increases serum Klotho levels in healthy volunteers. <i>Journal of Circulating Biomarkers</i> , 2018, 7, 184945441879458.	1.3	23
33	Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?. <i>Nephrology</i> , 2017, 22, 36-41.	1.6	10
34	Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. <i>Nephrology</i> , 2017, 22, 47-50.	1.6	11
35	Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. <i>Nature</i> , 2017, 545, 243-247.	27.8	181
36	Fetuin-A in the peritoneal effluent of patients with encapsulating peritoneal sclerosis—more than a protein?. <i>Kidney International</i> , 2017, 92, 1289-1290.	5.2	6

#	ARTICLE	IF	CITATIONS
37	FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF- β 2 autoinduction. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 92, 63-78.	2.8	55
38	The Role of Secondary Calciprotein Particles in the Mineralisation Paradox of Chronic Kidney Disease. <i>Calcified Tissue International</i> , 2017, 101, 570-580.	3.1	19
39	FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. <i>Scientific Reports</i> , 2017, 7, 3345.	3.3	75
40	A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. <i>Scientific Reports</i> , 2017, 7, 5686.	3.3	62
41	Nanoflow-Nanospray Mass Spectrometry Metabolomics Reveals Disruption of the Urinary Metabolite Profiles of HIV-Positive Patients on Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e45-e53.	2.1	12
42	Changes in Markers of Mineral Metabolism After Living Kidney Donation. <i>Transplantation Direct</i> , 2017, 3, e150.	1.6	6
43	Introduction of Renal Key Performance Indicators Associated with Increased Uptake of Peritoneal Dialysis in a Publicly Funded Health Service. <i>Peritoneal Dialysis International</i> , 2017, 37, 198-204.	2.3	7
44	Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 180-184.	2.9	13
45	Soluble klotho may be a marker of phosphate reabsorption. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 397-404.	2.9	12
46	Epigenetic Modifications to H3K9 in Renal Tubulointerstitial Cells after Unilateral Ureteric Obstruction and TGF- β 1 Stimulation. <i>Frontiers in Pharmacology</i> , 2017, 8, 307.	3.5	38
47	Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype – Role of Risk Factors and Epigenetics. <i>Frontiers in Pharmacology</i> , 2017, 8, 520.	3.5	54
48	Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1583-1587.	0.7	55
49	Hodgkin's Lymphoma Diagnosed from Peritoneal Effluent. <i>Peritoneal Dialysis International</i> , 2016, 36, 350-351.	2.3	7
50	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. <i>Nephrology</i> , 2016, 21, 535-546.	1.6	29
51	Emerging role of high-resolution imaging in the detection of renal osteodystrophy. <i>Nephrology</i> , 2016, 21, 801-811.	1.6	8
52	Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. <i>Nephrology</i> , 2016, 21, 46-54.	1.6	6
53	Relationship between timed and spot urine collections for measuring phosphate excretion. <i>International Urology and Nephrology</i> , 2016, 48, 115-124.	1.4	9
54	Use of a pre-analysis osmolality normalisation method to correct for variable urine concentrations and for improved metabolomic analyses. <i>Journal of Chromatography A</i> , 2016, 1431, 103-110.	3.7	42

#	ARTICLE	IF	CITATIONS
55	Platelet counts in autosomal dominant polycystic kidney disease. <i>Platelets</i> , 2016, 27, 262-263.	2.3	7
56	An In Vitro Murine Model of Vascular Smooth Muscle Cell Mineralization. <i>Methods in Molecular Biology</i> , 2016, 1397, 209-220.	0.9	7
57	Renal allograft re-use and herpetic re-infection. <i>Nephrology</i> , 2015, 20, 17-21.	1.6	7
58	Climate change and us: What nephrologists should know. <i>Nephrology</i> , 2015, 20, 760-764.	1.6	5
59	Assessing the utility of testing aluminum levels in dialysis patients. <i>Hemodialysis International</i> , 2015, 19, 256-262.	0.9	12
60	Relative abundance of fetuin-A in peritoneal dialysis effluent and its association with in situ formation of calciprotein particles: An observational pilot study. <i>Nephrology</i> , 2015, 20, 6-10.	1.6	12
61	Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology. <i>Frontiers in Immunology</i> , 2015, 6, 465.	4.8	39
62	FP061IS THROMBOCYTOPAENIA IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE REAL ?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii84-iii85.	0.7	0
63	SP658EFFECTS OF CINACALCET USE ON POST TRANSPLANT MINERAL METABOLISM. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii595-iii595.	0.7	0
64	Diurnal variation and short-term pre-analytical stability of serum soluble β -klotho in healthy volunteers: a pilot study. <i>Annals of Clinical Biochemistry</i> , 2015, 52, 506-509.	1.6	8
65	Peritoneal Dialysis for Heart Failure. <i>Peritoneal Dialysis International</i> , 2015, 35, 645-649.	2.3	27
66	The Gut in Older Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2015, 35, 650-654.	2.3	20
67	The role of fetuin-A in mineral trafficking and deposition. <i>BoneKEy Reports</i> , 2015, 4, 672.	2.7	48
68	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I " Assessment and Management of Various Cardiovascular Risk Factors. <i>Peritoneal Dialysis International</i> , 2015, 35, 379-387.	2.3	123
69	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II " Management of Various Cardiovascular Complications. <i>Peritoneal Dialysis International</i> , 2015, 35, 388-396.	2.3	55
70	Fibroblast growth factor 23. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 203-227.	1.6	53
71	Increasing home dialysis knowledge through a web-based e-learning program. <i>Nephrology</i> , 2014, 19, 345-351.	1.6	9
72	A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. <i>AIDS Research and Therapy</i> , 2014, 11, 35.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Old tracer for a new purpose. <i>Nuclear Medicine Communications</i> , 2014, 35, 1058-1066.	1.1	1
74	An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis. <i>Journal of Materials Science: Materials in Medicine</i> , 2014, 25, 1589-1597.	3.6	28
75	The importance of klotho in phosphate metabolism and kidney disease. <i>Nephrology</i> , 2014, 19, 439-449.	1.6	29
76	Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 339-348.	6.1	198
77	Providing a Peritoneal Dialysis Service. , 2014, , 705-716.		1
78	C-terminal FGF23 fragments: present but not seen?. <i>Osteoporosis International</i> , 2013, 24, 1933-1934.	3.1	0
79	FGF23: instability may affect accuracy and interpretation. <i>Osteoporosis International</i> , 2013, 24, 1135-1136.	3.1	1
80	Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. <i>Nephrology</i> , 2013, 18, 215-221.	1.6	81
81	Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD). <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1569-1579.	0.7	65
82	Does a Patent Foramen Ovale Influence Cognitive Function in Dialysis Patients?. <i>Nephron Clinical Practice</i> , 2013, 123, 1-6.	2.3	3
83	Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1971-1981.	2.3	55
84	Fetuin-A-containing calciprotein particle levels can be reduced by dialysis, sodium thiosulphate and plasma exchange. Potential therapeutic implications for calciphylaxis?. <i>Nephrology</i> , 2013, 18, 724-727.	1.6	21
85	Large vessel calcification in Takayasu arteritis. <i>Internal Medicine Journal</i> , 2013, 43, 584-587.	0.8	9
86	The value of urinary neutrophil gelatinase-associated lipocalin in risk prediction of renal decline in patients with chronic kidney disease. <i>Kidney International</i> , 2013, 84, 216-217.	5.2	2
87	Fetuin-A-Containing Calciprotein Particles Reduce Mineral Stress in the Macrophage. <i>PLoS ONE</i> , 2013, 8, e60904.	2.5	138
88	Renal and Hepatic Kinetics of Tc-99m-labelled Hexakis-methoxy-isobutyl Isonitrite. <i>Drug Metabolism Letters</i> , 2013, 6, 242-246.	0.8	1
89	Elastin Degradation Is Associated With Progressive Aortic Stiffening and All-Cause Mortality in Predialysis Chronic Kidney Disease. <i>Hypertension</i> , 2012, 59, 973-978.	2.7	63
90	Hyperparathyroidism in chronic kidney disease: complexities within the commonplace. <i>Clinical Medicine</i> , 2012, 12, 333-337.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1957-1966.	0.7	156
92	The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1534-1541.	0.7	77
93	FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 727-733.	0.7	52
94	Patent foramen ovale, dialysis and microembolization. <i>Nephrology</i> , 2012, 17, 569-574.	1.6	9
95	Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3357-3365.	3.6	178
96	Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. <i>BMC Nephrology</i> , 2012, 13, 40.	1.8	7
97	FGF23 adds value to risk prediction in patients with chronic kidney disease. <i>Bone</i> , 2012, 51, 830-831.	2.9	5
98	Review article: vitamin D and inflammatory bowel disease – established concepts and future directions. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 324-344.	3.7	91
99	Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. <i>HIV Medicine</i> , 2012, 13, 526-532.	2.2	24
100	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009–2012). <i>Nephron Clinical Practice</i> , 2011, 118, c27-c70.	2.3	23
101	Instability of fibroblast growth factor-23 (FGF-23): Implications for clinical studies. <i>Clinica Chimica Acta</i> , 2011, 412, 1008-1011.	1.1	44
102	Is the kidney just a modified blood vessel? Unravelling the direction of causality between cardiovascular and renal disease. <i>Atherosclerosis</i> , 2011, 216, 275-276.	0.8	5
103	Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. <i>BMJ Case Reports</i> , 2011, 2011, bcr0520114287-bcr0520114287.	0.5	6
104	Liver disease and renal dysfunction. <i>Medicine</i> , 2011, 39, 492-496.	0.4	5
105	Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD. <i>Nephron Clinical Practice</i> , 2011, 118, c125-c144.	2.3	14
106	The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1752-1753.	0.7	3
107	Factors associated with increasing vascular stiffness in PD. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2060-2061.	0.7	0
108	Important Differences in Measurement of Fetuin-A. <i>Annals of Internal Medicine</i> , 2010, 153, 419.	3.9	9

#	ARTICLE	IF	CITATIONS
109	Response to Macrocirculation Meets Microcirculation. Hypertension, 2010, 56, .	2.7	0
110	Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrology Dialysis Transplantation, 2010, 25, 1853-1858.	0.7	52
111	Poor agreement between commercial ELISAs for plasma fetuin-A: An effect of protein glycosylation?. Clinica Chimica Acta, 2010, 411, 1367-1370.	1.1	35
112	Aortic Stiffness Is Independently Associated With Rate of Renal Function Decline in Chronic Kidney Disease Stages 3 and 4. Hypertension, 2010, 55, 1110-1115.	2.7	184
113	Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. Nephrology Dialysis Transplantation, 2009, 24, 3751-3755.	0.7	24
114	Thalidomide-induced heart block in a dialysis patient. CKJ: Clinical Kidney Journal, 2009, 2, 507-508.	2.9	2
115	Spectrum of chronic kidney disease in HIV-infected patients. HIV Medicine, 2009, 10, 329-336.	2.2	140
116	Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Aids, 2009, 23, 2517-2521.	2.2	48
117	Recent developments in HIV and the kidney. Current Opinion in Infectious Diseases, 2009, 22, 43-48.	3.1	46
118	Predictors of Renal Outcome in HIV-Associated Nephropathy. Clinical Infectious Diseases, 2008, 46, 1282-1289.	5.8	103
119	Rhabdomyolysis and Compartment Syndrome. Competency-based Critical Care, 2008, , 38-41.	0.0	1
120	Liver disease and renal dysfunction. Medicine, 2007, 35, 521-523.	0.4	1
121	Granulomatous interstitial nephritis treated with a tumour necrosis factor- α inhibitor. Nephrology Dialysis Transplantation, 2006, 21, 2311-2314.	0.7	3
122	Treatment of unilateral obstruction reversing heavy and bilateral proteinuria. Nephrology Dialysis Transplantation, 2005, 20, 210-212.	0.7	8
123	The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrology Dialysis Transplantation, 2005, 20, 2867-2868.	0.7	7
124	Dialysis independence following radiotherapy of renal extramedullary haemopoiesis. Nephrology Dialysis Transplantation, 2004, 19, 1310-1312.	0.7	1
125	Acute transplant rejection induced by blood transfusion reaction to the Kidd blood group system. Nephrology Dialysis Transplantation, 2004, 19, 2403-2406.	0.7	25
126	Renal involvement in an Anderson-Fabry heterozygote. Postgraduate Medical Journal, 2002, 78, 759-759.	1.8	0

#	ARTICLE	IF	CITATIONS
127	The potential usefulness of vitamin C as an anti-oxidant?. Intensive Care Medicine, 2002, 28, 1186-1186.	8.2	0
128	Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Medicine, 2001, 27, 803-811.	8.2	245
129	Atrial thrombus and central venous dialysis catheters. American Journal of Kidney Diseases, 2001, 38, 631-639.	1.9	77
130	Alcoholic hepatitis---the case for intensive management. Postgraduate Medical Journal, 2000, 76, 504-507.	1.8	8
131	A chemiluminescence-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. Free Radical Research, 2000, 32, 1-9.	3.3	153
132	The reappearing kidney: an unusual complication of renal biopsy. Nephrology Dialysis Transplantation, 1999, 14, 1758-1760.	0.7	0
133	Acute cholestasis-induced renal failure: Effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney International, 1999, 55, 271-277.	5.2	81
134	Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic rat. Hepatology, 1999, 30, 1198-1205.	7.3	100
135	Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet, The, 1999, 353, 294-295.	13.7	165
136	The National Health Service Breast Screening Programme in the Trent region---are we meeting the targets?. European Journal of Surgical Oncology, 1998, 24, 99-103.	1.0	1
137	A Causative Role for Redox Cycling of Myoglobin and Its Inhibition by Alkalinization in the Pathogenesis and Treatment of Rhabdomyolysis-induced Renal Failure. Journal of Biological Chemistry, 1998, 273, 31731-31737.	3.4	234
138	Cytokine nephropathy and multi-organ dysfunction in lymphoma. Nephrology Dialysis Transplantation, 1998, 13, 1853-1857.	0.7	7
139	Further Evidence for an Interaction between Alcohol and Certain H2-Receptor Antagonists. Alcoholism: Clinical and Experimental Research, 1991, 15, 1084-1085.	2.4	31